NeOnc
Beyond's analysis on NeOnc
- — NeOnc CEO insider buying signals confidence ahead of critical regulatory milestones for NEO100
- — NeOnc Technologies completes Phase 2a trial, awaiting FDA guidance following clinical data readout
Recent news mentioning NeOnc
- — Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
- — NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
- — NeOnc' Phase 2 Data Could Put Cancer on the Ropes
- — NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears
- — NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
- — NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma